1 year results of the ustekinumab in SLE trial encouraging. 1st 6 mos DBRPCT showed UST 62% vs PBO 33%. At wk 48 UST SRI4 responses maintained 63.3%; PBO crossovers caught up. 15% had seriour adverse events. https://t.co/XauG4JOJIj